AUTL Autolus Therapeutics plc

+1.76  (+6%)
Previous Close 27.13
Open 27.12
Price To Book 4.54
Market Cap 1159823198
Shares 40,146,182
Volume 19,318
Short Ratio
Av. Daily Volume 69,949

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase initial data due 1H 2019.
T-cell lymphoma
Phase 1/2 data presented at ASH December 2018.
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1/2 trial initiated 3Q 2017. Phase 1 part of trial to be completed 4Q 2019.
Relapsed or refractory multiple myeloma
Phase 1 updated data noted 12/14 (86%) achieved molecular CR; OS 84% and 63% at 6 and 12 months, respectively - February 19, 2019.
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
T-cell lymphoma

Latest News

  1. Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
  2. Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
  3. Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
  4. Alexandria Fully Leases New Built-to-Suit Facility to Autolus
  5. Biotech to create 170 jobs, invest $28M in new Rockville HQ
  6. Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters
  7. MoCo economic development officials plan satellite office in Boston
  8. London biotech firm planning new U.S. HQ, research facility in Rockville
  9. Autolus Therapeutics to Join NASDAQ Biotechnology Index
  10. Arix Bioscience plc: Autolus Announces Update on AUTO4 and AUTO5 Programmes
  11. Arix Bioscience plc: Autolus Presents Initial AUTO3 Clinical Data at ASH
  12. Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting
  13. Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
  14. Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F
  15. Autolus Therapeutics to Present New Data at the ASH Annual Meeting
  16. Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 60th ASH Annual Meeting
  17. Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference
  18. Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
  19. UK biotech raises bumper $2 billion, despite Brexit blues
  20. T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics